Skip To Main Content
Emiliano Calvo on Muck Rack

Emiliano Calvo

As seen in: Nature, The Oncologist, MDPI, The Lancet, Cell Press, Health Tech World, Cancer Treatment Reviews, Pharma Focus Europe
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Emiliano

Contact Emiliano, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

An anti-PMEL antibody−drug conjugate with a G q/1 1 inhibitor payload in GNAQ / GNA11 -mutant melanomas: a phase 1 trial

|
By Matteo S. Carlino, Ellen Kapiteijn, Sophie Piperno-Neumann, Ryan Sullivan, Richard D Carvajal, Reinhard Dummer, Tanja Gromke, Jessica C Hassel, Damien Kee, Egle Ramelyte, Alexander N. Shoushtari, Alexander Wei, Alexander H. Enk, Heike Richly, Manuel Jorge Rodrigues, Shahneen Sandhu, James W. Smithy, Frank M. Speetjens, Pedro Milanez-Almeida, Anwesha Chaudhury, Mary E. Ising, Javier Otero, Aimee Reynolds, Lillian Werner, Emiliano Calvo, Eleanor E. Handel, Kamaneh Montazeri, Jorge Ramon-Patino, Keith Hoffmaster, Thiruvamoor RamKumar, Sherif Sharaby, Padmaja Yerramilli-Rao
| Nature Verified
Abstract Metastatic uveal melanoma (mUM) is an aggressive cancer with limited treatment options; 85−90% of tumors harbor activating GNAQ and GNA11 mutations. Uveal melanoma cells also express PMEL (also known as PMEL17 or gp100), a melanocyte lineage antigen. DYP688, a novel biology-matched antibody−drug conjugate, binds surface PMEL and delivers the potent Gαq/Gα11 (Gq/11) inhibitor SDZ475 as payload by internalization.
Open in Who Shared Issue with article?

Fine-Tuning ADCs to Improve Outcomes for Patients with Cancer

|
By Emiliano Calvo
| Pharma Focus Europe Verified
Antibody-drug conjugates (ADCs) have emerged as one of the most promising therapeutic modalities in oncology, combining the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapy. By delivering highly potent payloads directly to tumour cells, ADCs aim to maximise anti-tumour activity while minimising systemic toxicity.
Open in Who Shared Issue with article?

Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours - Nature

|
By Ignacio Melero, Elena Garralda, Martin Schuler, Reinhard Dummer, Emiliano Calvo, Jorge Esteban-Villarrubia, Paula Sabat, Juan José Soto-Castillo, Kira-Lee Koster, Tanja Gromke, Ana Landa-Magdalena, Irene Ramos Moreno, Javier Torres-Jiménez, Andreas Schmitt, Anna Vilalta-Lacarra, Jörg Trojan, Zlatko Trajanoski, Hubert Hackl, Falk Gogolla, Florestan J. Koll, Matthias Machacek, Wolf H. Fridman, Ralf Bargou, Markus Haake, Ana Gjorgjioska, Bernhard Rössler, Marlene Auer, Kathrin Klar
| Nature Verified
Abstract Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved cancer treatment1. Yet, response rates are still limited, and tumour progression commonly occurs2. Soluble and cell-bound factors in the tumour microenvironment negatively affect cancer immunity.
Open in Who Shared Issue with article?
See all 20 articles